EUVIMEDEUVIMED entdecken
Crossref

Systemic sclerosis-associated interstitial lung disease complicated by precapillary pulmonary hypertension: a real-world case

Feyzullah Esat Yazar

Journal of Pulmonology and Intensive Care · 28.10.2026 · 4 (4) · 123-126

DOI: 10.51271/jopic-0092 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Pulmonology and Intensive Care, online erschienen am 28.10.2026. Verfasst von Feyzullah Esat Yazar.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Systemic sclerosis (SSc) is a rare autoimmune disease characterized by widespread vasculopathy and progressive fibrosis. Pulmonary involvement, particularly interstitial lung disease (ILD) and pulmonary hypertension (PH), is among the leading causes of morbidity and mortality in these patients. Herein, we present a case of precapillary pulmonary hypertension that developed following interstitial lung disease (SSc-ILD) in a patient with systemic sclerosis. Case Presentation: A 60-year-old woman diagnosed with systemic sclerosis in 2019 based on positive antinuclear antibody (ANA) and anti-Scl-70 antibody findings was referred to our outpatient clinic with progressively worsening exertional dyspnea. Initial evaluation revealed a marked reduction in diffusing capacity for carbon monoxide (DLCO, 24% predicted) and a cellular nonspecific interstitial pneumonia (NSIP) pattern on high-resolution computed tomography (HRCT). Over the following years, the NSIP pattern progressed from a cellular to a fibrotic phenotype, accompanied by significant clinical deterioration by 2022. As the disease progressed to the fibrotic stage and the patient was diagnosed with progressive pulmonary fibrosis, nintedanib therapy was initiated. Right heart catheterization revealed a mean pulmonary artery pressure of 39 mmHg, confirming precapillary pulmonary hypertension and leading to a diagnosis of Group 1 pulmonary arterial hypertension (PAH). Macitentan was initiated for PAH, while nintedanib, administered for ILD, had to be discontinued because of gastrointestinal intolerance. Despite partial improvement in pulmonary artery pressures, pulmonary function continued to deteriorate, with DLCO declining to 13% predicted. The patient died of cardiopulmonary arrest in 2024.

Conclusion

The coexistence of SSc-ILD and pulmonary hypertension represents a severe clinical phenotype associated with a poor prognosis. A progressive decline in DLCO may serve as a sensitive functional marker of the development of pulmonary vascular disease, while right heart catheterization remains the gold standard for definitive diagnosis. Early recognition and individualized management are crucial for optimizing outcomes in these complex patients.

Zitieren

APA

Yazar, F. E. (2026). Systemic sclerosis-associated interstitial lung disease complicated by precapillary pulmonary hypertension: a real-world case. Journal of Pulmonology and Intensive Care, 4(4), 123-126. https://doi.org/10.51271/jopic-0092

Vancouver

Yazar FE. Systemic sclerosis-associated interstitial lung disease complicated by precapillary pulmonary hypertension: a real-world case. Journal of Pulmonology and Intensive Care. 2026;4(4):123-126. doi:10.51271/jopic-0092

BibTeX
@article{Yazar2026,
  author = {Yazar, Feyzullah Esat},
  title = {Systemic sclerosis-associated interstitial lung disease complicated by precapillary pulmonary hypertension: a real-world case},
  journal = {Journal of Pulmonology and Intensive Care},
  year = {2026},
  volume = {4},
  number = {4},
  pages = {123--126},
  doi = {10.51271/jopic-0092}
}
Kostenlos starten →